Security
BioAge Labs, Inc. Common Stock · BIOA
BIOANASDAQCommon stockCurrentCIK 1709941Updated Nov 9, 2026
BIOA price & chart
Loading TradingView…
NASDAQ:BIOA on TradingView ↗About the company
BioAge is a clinical-stage biopharmaceutical company developing therapeutic product candidates for cardiometabolic diseases by targeting the biology of human aging. The Company's lead product candidate, BGE-102, is a potent, orally bioavailable, brain-penetrant small-molecule NLRP3 inhibitor being developed for diseases driven by inflammation, including diabetic macular edema and cardiovascular risk. BGE-102 has completed a Phase 1 SAD/MAD trial demonstrating a well-tolerated profile and potential best-in-class reductions in hsCRP and other inflammatory biomarkers. Phase 2 cardiovascular proof-of-concept data from QUELL-CV are anticipated in the fourth quarter of 2026, and Phase 2 diabetic macular edema data from QUELL-DME are anticipated in the second half of 2027. The Company is also developing long-acting injectable and oral small molecule APJ agonists for obesity. BioAgeʼs additional preclinical programs, which leverage insights from the Companyʼs proprietary discovery platform built on human longevity data, address key pathways involved in metabolic aging.
In the news
BioAge Labs to Present at Upcoming Investor Conferences ↗
Final Deadline for the BioAge Labs, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - BIOA News provided by DJS Law Group LLP Mar 10, 2025, 21:30 ET Share this article Share to X Share this article Share to X LOS ANGELES , March 10, 2025 /PRNewswire/ -- The DJS Law Group ↗
BIOA Deadline Today: BIOA Investors Have Opportunity to Lead BioAge Labs, Inc. Securities Lawsuit News provided by THE ROSEN LAW FIRM, P. A. Mar 10, 2025, 18:33 ET Share this article Share to X Share this article Share to X NEW YORK , March 10, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global inv ↗
Seeking Alpha
BioAge Labs GAAP EPS of -$0.73 misses by $0.09, revenue of $0.3M misses by $1.18M ↗
10 small-cap U.S. healthcare stocks with the weakest momentum grades ↗
BioAge Labs, Inc. (BIOA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript ↗
SEC disclosures
BioAge Labs, Inc. files 8-K: Material Event ↗
Recent filings
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Other Events
Items 8.01
SCHEDULE 13G/A - filed by Cormorant Asset Management, LP regarding BioAge Labs, Inc.
10-Q filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||||
| AssetsUSD | 305,090,000Source | 337,381,000Source | 396,929,000Source | 322,148,000Source | — | 397,654,000Source | 343,841,000Source | — | 294,889,000Source | 358,234,000Source | 25,924,000Source |
| Property, Plant and Equipment, NetUSD | 973,000Source | 543,000Source | 1,209,000Source | 974,000Source | — | 1,115,000Source | 929,000Source | — | 963,000Source | 591,000Source | 323,000Source |
| Current assets: | |||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 215,573,000Source | 334,474,000Source | 73,964,000Source | 220,330,000Source | — | 241,777,000Source | 257,486,000Source | 173,992,000Source | 188,888,000Source | 354,349,000Source | 21,644,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 515,000Source | — | 625,000Source | 603,000Source | — | 709,000Source | 361,000Source | — | 769,000Source | — | — |
| Assets, CurrentUSD | 290,828,000Source | 336,467,000Source | 330,312,000Source | 301,697,000Source | — | 391,860,000Source | 324,813,000Source | — | 286,793,000Source | 357,103,000Source | 25,306,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 4,535,000Source | 1,993,000Source | 10,942,000Source | 3,799,000Source | — | 7,957,000Source | 3,934,000Source | — | 4,926,000Source | 2,754,000Source | 349,000Source |
| Operating Lease, Right-of-Use AssetUSD | 2,884,000Source | 271,000Source | 2,582,000Source | 3,032,000Source | — | 2,684,000Source | 3,201,000Source | — | 2,785,000Source | 200,000Source | 195,000Source |
| Other Assets, NoncurrentUSD | 227,000Source | — | 208,000Source | 237,000Source | — | 215,000Source | 239,000Source | — | 216,000Source | 240,000Source | — |
| LIABILITIES AND EQUITY | |||||||||||
| LiabilitiesUSD | 27,626,000Source | 23,633,000Source | 22,016,000Source | 27,367,000Source | — | 18,533,000Source | 30,674,000Source | — | 22,838,000Source | 35,107,000Source | 66,598,000Source |
| Stockholders’ equity: | |||||||||||
| Preferred Stock, Value, IssuedUSD | 0Source | — | 0Source | 0Source | — | 0Source | — | — | 0Source | — | — |
| Common Stock, Value, IssuedUSD | 0Source | — | 0Source | 0Source | — | 0Source | — | — | 0Source | 0Source | 0Source |
| Additional Paid in CapitalUSD | 584,662,000Source | 545,321,000Source | 757,157,000Source | 581,871,000Source | — | 734,717,000Source | 578,642,000Source | — | 605,189,000Source | 575,693,000Source | 8,142,000Source |
| Retained Earnings (Accumulated Deficit)USD | -307,473,000Source | -231,682,000Source | -381,766,000Source | -287,302,000Source | — | -355,669,000Source | -265,739,000Source | — | -333,416,000Source | -252,811,000Source | -181,702,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 275,000Source | 109,000Source | -478,000Source | 212,000Source | — | 73,000Source | 264,000Source | — | 278,000Source | 245,000Source | 164,000Source |
| Stockholders' Equity Attributable to ParentUSD | 277,464,000Source | 313,748,000Source | 374,913,000Source | 294,781,000Source | -197,131,000Source | 379,121,000Source | 313,167,000Source | -185,512,000Source | 272,051,000Source | 323,127,000Source | -173,396,000Source |
| Liabilities and EquityUSD | 305,090,000Source | 337,381,000Source | 396,929,000Source | 322,148,000Source | — | 397,654,000Source | 343,841,000Source | — | 294,889,000Source | 358,234,000Source | 25,924,000Source |
| Current liabilities: | |||||||||||
| Liabilities, CurrentUSD | 24,493,000Source | 19,080,000Source | 19,217,000Source | 22,837,000Source | — | 15,827,000Source | 23,738,000Source | — | 20,138,000Source | 27,775,000Source | 58,168,000Source |
| Operating Lease, Liability, CurrentUSD | 580,000Source | 273,000Source | 714,000Source | 630,000Source | — | 646,000Source | 700,000Source | — | 582,000Source | 202,000Source | 194,000Source |
| Accounts Payable, CurrentUSD | 5,018,000Source | 2,098,000Source | 5,653,000Source | 1,329,000Source | — | 3,066,000Source | 3,989,000Source | — | 2,674,000Source | 1,996,000Source | 1,866,000Source |
| Operating Lease, Liability, NoncurrentUSD | 2,427,000Source | — | 2,121,000Source | 2,520,000Source | — | 2,229,000Source | 2,556,000Source | — | 2,330,000Source | — | — |
| Additional Financial Items | |||||||||||
| Long-term Debt, Current MaturitiesUSD | 4,126,000Source | 6,000,000Source | 0Source | 5,596,000Source | — | 1,159,000Source | 6,000,000Source | — | 2,648,000Source | 6,000,000Source | 6,000,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | 0Source | 3,940,000Source | — | 0Source | — | — | 1,056,000Source | — | 0Source | 2,502,000Source | 8,201,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | |||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -22,253,000Source | -12,928,000Source | -80,605,000Source | -71,109,000Source | -63,854,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | |||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 4,256,000Source | 2,949,000Source | 11,691,000Source | 6,979,000Source | 3,016,000Source |
| Changes in operating assets and liabilities: | |||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | -60,000Source | 361,000Source | 769,000Source | — | — |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 326,000Source | 2,047,000Source | 788,000Source | 6,000Source | -393,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -24,046,000Source | -17,363,000Source | -81,627,000Source | -51,522,000Source | -37,362,000Source |
| Cash flows from investing activities: | |||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -46,753,000Source | -77,988,000Source | -95,216,000Source | -366,000Source | -266,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 26,000Source | 426,000Source | 719,000Source | 366,000Source | 166,000Source |
| Cash flows from financing activities: | |||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 123,715,000Source | -1,500,000Source | 11,469,000Source | 381,199,000Source | 34,941,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 52,889,000Source | -96,863,000Source | -165,461,000Source | 329,392,000Source | -2,687,000Source |
| Supplemental disclosure of cash flow information: | |||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 41,000Source | 217,000Source | 611,000Source | 1,420,000Source | 1,155,000Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 0Source | — | — |
| Additional Financial Items | |||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 2,791,000Source | 1,848,000Source | 4,269,000Source | 3,229,000Source | 4,256,000Source | 2,949,000Source | 11,691,000Source | 6,979,000Source | 3,016,000Source |
| DepreciationUSD | — | — | — | — | — | — | — | — | 200,000Source | 200,000Source | 200,000Source |
| Depreciation, NonproductionUSD | — | — | — | — | — | — | 63,000Source | 37,000Source | 213,000Source | 167,000Source | 162,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | — | — | -23,000Source | -55,000Source | — |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | 0Source | 0Source | — | 0Source | — | 0Source | 0Source | -250,000Source | — |
| General and Administrative ExpenseUSD | — | — | 6,681,000Source | 4,731,000Source | 7,419,000Source | 7,339,000Source | 7,737,000Source | 6,788,000Source | 27,809,000Source | 19,158,000Source | 14,514,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source |
| InterestExpenseNonoperatingUSD | — | — | 149,000Source | 388,000Source | 1,000Source | 201,000Source | 39,000Source | 255,000Source | 697,000Source | 2,367,000Source | 7,794,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -20,171,000Source | -23,407,000Source | -26,097,000Source | -21,563,000Source | -22,253,000Source | -12,928,000Source | -80,605,000Source | -71,109,000Source | -63,854,000Source |
| Nonoperating Income (Expense)USD | — | — | 2,969,000Source | 1,343,000Source | 3,236,000Source | 3,208,000Source | 3,122,000Source | 3,518,000Source | 12,175,000Source | 7,085,000Source | -15,454,000Source |
| Operating ExpensesUSD | — | — | 25,194,000Source | 24,750,000Source | 31,784,000Source | 27,183,000Source | 28,147,000Source | 17,897,000Source | 101,775,000Source | 78,194,000Source | 48,400,000Source |
| Operating Lease, ExpenseUSD | — | — | 200,000Source | 100,000Source | 200,000Source | 400,000Source | 200,000Source | 100,000Source | 800,000Source | — | — |
| Payments of Financing CostsUSD | — | — | — | — | — | — | 91,000Source | 0Source | 336,000Source | — | — |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | 17,155,000Source | — | — |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 1,707,000Source | 0Source | 714,000Source | 634,000Source | 4,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | — | — | — | — | — | — | — | —Source | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 2,054,000Source | 0Source | 2,451,000Source | 2,412,000Source | 2,772,000Source | 1,451,000Source | 8,995,000Source | — | — |
| Operating Income (Loss)USD | — | — | -23,140,000Source | -24,750,000Source | -29,333,000Source | -24,771,000Source | -25,375,000Source | -16,446,000Source | -92,780,000Source | -78,194,000Source | -48,400,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | -80,605,000Source | -71,109,000Source | -63,854,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -20,171,000Source | -23,407,000Source | -26,097,000Source | -21,563,000Source | -22,253,000Source | -12,928,000Source | -80,605,000Source | -71,109,000Source | -63,854,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.56Source | -6.7Source | -0.58Source | -0.6Source | -0.52Source | -0.36Source | -2.24Source | -6.63Source | -38.17Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.56Source | -6.7Source | -0.58Source | -0.6Source | -0.52Source | -0.36Source | -2.24Source | -6.63Source | -38.17Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 35,850,037Source | 3,494,580Source | 44,838,893Source | 35,850,037Source | 42,480,488Source | 35,850,037Source | 35,932,914Source | 10,726,521Source | 1,672,793Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 35,850,037Source | 3,494,580Source | 44,838,893Source | 35,850,037Source | 42,480,488Source | 35,850,037Source | 35,932,914Source | 10,726,521Source | 1,672,793Source |
| Interest Expense (non-operating)USD | — | — | 149,000Source | 388,000Source | 1,000Source | 201,000Source | 39,000Source | 255,000Source | 697,000Source | 2,367,000Source | 7,794,000Source |
| Additional Financial Items | |||||||||||
| General and Administrative ExpenseUSD | — | — | 6,681,000Source | 4,731,000Source | 7,419,000Source | 7,339,000Source | 7,737,000Source | 6,788,000Source | 27,809,000Source | 19,158,000Source | 14,514,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -80,585,000Source | -71,094,000Source | -64,140,000Source |
| Interest and Other IncomeUSD | — | — | 3,160,000Source | 2,037,000Source | 3,438,000Source | 3,420,000Source | 3,268,000Source | 3,714,000Source | 13,086,000Source | 9,629,000Source | 2,431,000Source |
| Nonoperating Income (Expense)USD | — | — | 2,969,000Source | 1,343,000Source | 3,236,000Source | 3,208,000Source | 3,122,000Source | 3,518,000Source | 12,175,000Source | 7,085,000Source | -15,454,000Source |
| Operating ExpensesUSD | — | — | 25,194,000Source | 24,750,000Source | 31,784,000Source | 27,183,000Source | 28,147,000Source | 17,897,000Source | 101,775,000Source | 78,194,000Source | 48,400,000Source |
| Operating Lease, ExpenseUSD | — | — | 200,000Source | 100,000Source | 200,000Source | 400,000Source | 200,000Source | 100,000Source | 800,000Source | — | — |
| Research and Development ExpenseUSD | — | — | 18,513,000Source | 20,019,000Source | 24,365,000Source | 19,844,000Source | 20,410,000Source | 11,109,000Source | 73,966,000Source | 59,036,000Source | 33,886,000Source |
Offerings
Registration 333-294568
Filing attachments
bioa-ex99_1.htm · 8-K · 2026-11-05
EXHIBIT 99.1 BioAge Labs Reports Third Quarter 2026 Financial Results and Provides Business Updates First participant dosed in QUELL-DME, a Phase 2 trial of BGE-102, a potential best-in-class oral NLRP3 inhibitor, in diabetic macular edema; topline results anticipated in the second half of 2027 QUELL-CV, a Phase 2 dose-ranging trial of BGE-102 in adults with obesity and elevated inflammation, completed enrollment; topline data anticipated in the fourth quarter of 2026 APJ agonist program, an…
Read attachment ↗bioa-ex99_1.htm · 8-K · 2026-08-05
EX-99.1 2 bioa-ex99_1.htm EX-99.1 EX-99.1 EXHIBIT 99.1 BioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business Updates First participant dosed in QUELL-CV, a Phase 2 dose-ranging proof-of-concept trial of BGE-102 measuring inflammatory and cardiometabolic biomarkers; topline data anticipated in the second half of 2026 QUELL-DME, Phase 1b/2a proof-of-concept trial of BGE-102 in diabetic macular edema, planned to initiate in mid-2026, with data anticipated in mid-20…
Read attachment ↗bioa-ex99_1.htm · 8-K · 2026-05-08
EX-99.1 2 bioa-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 BioAge Labs Reports First Quarter 2026 Financial Results and Provides Business Updates Positive topline Phase 1 data for BGE-102, demonstrating potential best-in-class reductions among oral NLRP3 inhibitors in inflammatory biomarkers of cardiovascular risk Phase 2 dose-ranging proof-of-concept trial of BGE-102 in cardiovascular risk planned to initiate in mid-2026, with data anticipated by end of year Phase 1b/2a proof-of-concept tr…
Read attachment ↗bioa-ex4_3.htm · S-3ASR · 2026-03-24
Exhibit 4.3 FORM OF DEBT SECURITY [Face of Security] BIOAGE LABS, INC. [If applicable, insert - FOR PURPOSES OF THE ORIGINAL ISSUE DISCOUNT PROVISIONS OF THE INTERNAL REVENUE CODE OF 1986, THE ISSUE PRICE OF THIS SECURITY IS % OF ITS PRINCIPAL AMOUNT AT STATED MATURITY SET FORTH BELOW (ITS “PRINCIPAL AMOUNT”), THE AMOUNT OF ORIGINAL ISSUE DISCOUNT IS % OF ITS PRINCIPAL AMOUNT, THE YIELD TO MATURITY IS % AND THE ISSUE DATE IS ] [IF THE SECURITY IS A GLOBAL SECURITY, INSERT - THIS NOTE IS A G…
Read attachment ↗bioa-ex4_4.htm · S-3ASR · 2026-03-24
Exhibit 4.4 BIOAGE LABS, INC. And , as Trustee INDENTURE Dated as of, TABLE OF CONTENTS Page Article 1 DEFINITIONS AND INCORPORATION BY REFERENCE 1 1.1 DEFINITIONS. …
Read attachment ↗bioa-ex99_1.htm · 8-K · 2026-03-24
EX-99.1 2 bioa-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 BioAge Labs Reports Full Year 2025 Financial Results and Provides Business Updates from the Fourth Quarter of 2025 Positive interim Phase 1 data for BGE-102, a potent, structurally novel, orally available, brain-penetrant small-molecule NLRP3 inhibitor, demonstrating potential best-in-class reductions in inflammatory biomarkers of cardiovascular risk; Phase 2a proof-of-concept trial planned to initiate in 1H 2026 Indication expansion…
Read attachment ↗